Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and
AbCellera (Nasdaq: ABCL) today announced a multi-year,
multi-program partnership to discover, develop, and commercialize
potentially first-in-class treatments for patients with cancer. The
collaboration combines Prelude’s expertise in targeted protein
degradation, medicinal chemistry, and clinical development with
AbCellera’s antibody discovery and development engine to generate
novel precision antibody drug conjugates (ADCs). The first program,
which benefits from a lead panel of antibodies previously
discovered by AbCellera, is focused on ADCs to broaden the reach of
Prelude’s small molecule SMARCA2 selective degraders to address a
larger patient population.
“By leveraging our combined capabilities and expertise in
rapidly discovering and advancing novel candidates into the clinic,
this collaboration provides an opportunity to build a pipeline of
first-in-class ADCs targeting clinically validated pathways in
oncology,” said Kris Vaddi, Ph.D., Founder and CEO of Prelude.
“Through this strategic partnership we are combining deep
expertise in antibody and small molecule development to create
precision ADC therapies for patients in need,” said Carl Hansen,
Ph.D., Founder and CEO of AbCellera.
Under the terms of the agreement, Prelude and AbCellera will
jointly discover, develop, and commercialize products emerging from
the collaboration. AbCellera will lead manufacturing activities and
Prelude will lead clinical development and global
commercialization, subject to AbCellera’s option to co-promote any
resulting commercial products in the United States.
About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology
company developing innovative drug candidates targeting critical
cancer cell pathways. The Company’s diverse pipeline is comprised
of highly differentiated, potentially best-in-class proprietary
small molecule compounds aimed at addressing clinically validated
pathways for cancers with selectable underserved patients.
Prelude’s pipeline includes four candidates currently in clinical
development: PRT1419, a potent, selective inhibitor of MCL1,
PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a
next generation CDK4/6 inhibitor, and PRT3789, an IV administered,
potent and highly selective SMARCA2 degrader, as well as an oral
SMARCA2 degrader that is currently in IND-enabling studies. For
more information, visit our website and follow us
on LinkedIn.
Prelude’s Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated discovery, preclinical and clinical
development activities. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. Although Prelude believes that the expectations
reflected in such forward-looking statements are reasonable,
Prelude cannot guarantee future events, results, actions, levels of
activity, performance or achievements, and the timing and results
of biotechnology development and potential regulatory approval is
inherently uncertain. Forward-looking statements are subject to
risks and uncertainties that may cause Prelude's actual activities
or results to differ significantly from those expressed in any
forward-looking statement, including risks and uncertainties
related to Prelude's ability to advance its product candidates, the
receipt and timing of potential regulatory designations, approvals
and commercialization of product candidates, clinical trial sites
and our ability to enroll eligible patients, supply chain and
manufacturing facilities, Prelude’s ability to maintain and
recognize the benefits of certain designations received by product
candidates, the timing and results of preclinical and clinical
trials, Prelude's ability to fund development activities and
achieve development goals, Prelude's ability to protect
intellectual property, and other risks and uncertainties described
under the heading "Risk Factors" in documents Prelude files from
time to time with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and Prelude undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date hereof.
About AbCellera Biologics Inc.
AbCellera is breaking the barriers of conventional antibody drug
discovery to bring better medicines to patients, sooner.
AbCellera’s engine integrates expert teams, technology, and
facilities with the data science and automation needed to propel
antibody-based medicines from target to clinic in nearly every
therapeutic area with precision and speed. AbCellera provides
innovative biotechs and leading pharmaceutical companies with a
competitive advantage that empowers them to move quickly, reduce
cost, and tackle the toughest problems in drug development. For
more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under “Risk Factors,” “Management's
Discussion and Analysis of Financial Condition and Results of
Operations” and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Prelude Contacts
Investors: Lindsey Trickett, Vice President, Investor Relations;
ltrickett@preludetx.com, +1(240)543-7970 Media: Helen Shik, Shik
Communications; helen@ShikCommunications.com, +1(617)510-4373
AbCellera Contacts
Media: Jessica Yingling, Ph.D.; media@abcellera.com,
+1(236)521-6774Business Development: Murray McCutcheon,
Ph.D.; bd@abcellera.com, +1(604)559-9005Investor Relations:
Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Apr 2024 to May 2024
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From May 2023 to May 2024